GlassScriptPhysician profile
Melissa Botero
NPI 1982246864
$1,166.82
in general payments reported to CMS, 2019-2025
16 companies · $414 in 2025
The $414 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $60.99 · 2022: $167 · 2023: $204 · 2024: $321 · 2025: $414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $826 · Education: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $826.35 |
| Education | $112.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $179.59 | 2023-2025 | Verzenio, Jaypirca, Retevmo |
| Janssen Biotech, INC. | $179.22 | 2021-2023 | Erleada, Rybrevant |
| Merck Sharp & Dohme LLC | $136.81 | 2023-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Daiichi Sankyo INC. | $122.81 | 2022-2025 | Enhertu |
| Novartis Pharmaceuticals Corporation | $105.54 | 2024 | |
| Tersera Therapeutics LLC | $96.32 | 2023-2025 | Zoladex |
| Genzyme Corporation | $67.54 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $54.06 | 2024 | Enhertu |
| Pfizer INC. | $50.65 | 2023-2025 | |
| Glaxosmithkline, LLC. | $33.12 | 2023-2025 | Zejula, Jemperli |
| Genentech USA, INC. | $31.07 | 2025 | Itovebi |
| Myriad Genetic Laboratories, INC. | $27.37 | 2025 | Myrisk |
| Seagen INC. | $24.54 | 2022 | |
| Stemline Therapeutics INC. | $22.93 | 2025 | Orserdu |
| Puma Biotechnology, INC. | $20.00 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agios Pharmaceuticals, INC. | $15.25 | 2025 | Pyrukynd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Botero listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.